Hijacking the Gut-Lung Axis to Treat COVID-19

Regulatory Hurdles

The challenges of navigating regulatory requirements in clinical trials are immense. Sabina Hazan expresses her frustration with the bureaucratic hurdles that delay essential research, particularly in the context of COVID-19 and autism treatments. She highlights the irony of spending more time on paperwork than patient care, stating, "It's not about taking care of the patients anymore. It's about taking care of the paperwork" 1. This bureaucratic maze not only hampers innovation but also prolongs the suffering of patients and their families, as seen in her struggle to initiate a clinical trial for autistic children 2.

   

Quality vs. Paperwork

The debate between ensuring product quality and managing excessive paperwork is a significant issue in clinical trials. Sabina argues that the focus should be on the quality of products rather than the overwhelming paperwork, which often hinders timely patient care. She emphasizes, "In our aim to protect the patient, we've killed the patient," pointing out the tragic delays in treatments for diseases like ALS and cancer 3. Additionally, she discusses the controversy surrounding drugs like Ivermectin, advocating for transparency and understanding of its origins and effects on the microbiome 4.